Lunaphore Technologies S.A. is a Swiss company founded in 2014 with the vision of bringing omics-like approaches to cancer research and tissue diagnostics and has been recognized as one of the most innovative companies nationally and internationally. Its award-winning technology based on microfluidics, known as FFeX (Fast Fluidic Exchange), enables ultra-rapid automation of sophisticated high-multiplicity tests with direct digitalization where applicable.